Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes

(NIH/National Heart, Lung and Blood Institute) A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of 'good' cholesterol, despite being treated with statins. The study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the Dec. 28 issue of JAMA Cardiology.